Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

Abstract Background Everolimus is an oral inhibitor of mammalian target of rapamycin, approved for metastatic renal cell carcinoma (mRCC). Recently, personalized medicine through therapeutic drug monitoring (TDM) is recommended in cancer therapy. In this study, the relationship between everolimus bl...

Full description

Bibliographic Details
Main Authors: Shinya Takasaki, Hiroaki Yamaguchi, Yoshihide Kawasaki, Masafumi Kikuchi, Masaki Tanaka, Akihiro Ito, Nariyasu Mano
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Everolimus
mTOR
Pharmacokinetics
Renal cell carcinoma
Therapeutic drug monitoring
Online Access:http://link.springer.com/article/10.1186/s40780-019-0135-5

Internet

http://link.springer.com/article/10.1186/s40780-019-0135-5

Similar Items